Industry
Biotechnology
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Loading...
Open
1.05
Mkt cap
72M
Volume
655K
High
1.07
P/E Ratio
-2.20
52-wk high
4.10
Low
0.99
Div yield
N/A
52-wk low
0.68
Portfolio Pulse from
November 12, 2024 | 3:45 pm
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 10:42 am
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
August 19, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:25 am
Portfolio Pulse from Benzinga Insights
July 26, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 11:25 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.